Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention

Completed · Phase 4

Conditions studied: Radial Artery Spasm, Angina, Coronary Artery Disease

In brief

The primary objective of the study is to determine the role of transdermal vasodilators as an adjunct to parenteral vasodilators in reducing radial artery spasm, improving patient comfort, and post procedure radial artery patency during transradial coronary angiograms and interventions. The study hypothesis is that transdermal vasodilators will increase radial artery size and reduce radial artery spasm as well as improve patient comfort and post procedure radial artery patency. This is a single-center, double-blind, randomized, placebo-controlled study comparing the effect of transdermal preparations of lidocaine + nitroglycerine and lidocaine + placebo on radial artery spasm in patients undergoing transdermal coronary angiograms. Prior to the procedure, each patient will be randomized into either the control arm, lidocaine + placebo, or study arm, lidocaine + nitroglycerine.

Key facts

Study ID

NCT02832115

Run by

Aultman Health Foundation

People needed

100

Starts

2016-09-01

Expected to finish

2019-05-02

Last updated by the study team

2020-10-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 18 years or older
• Radial artery catheterization

You may not qualify if…

• Hypersensitivity or contraindication to lidocaine
• Hypersensitivity or contraindication to nitroglycerine
• Recent use of phosphodiesterase 5 inhibitors (<24 hours after sildenafil or vardenafil; <48 hours after tadalafil)
• Baseline weak radial pulse (0 or 1+)
• Baseline hypotension SBP < 100 mmHg at the time of enrollment
• Dizziness or light-headedness at the time of enrollment
• Severe Aortic Stenosis or Hypertrophic obstructive cardiomyopathy
• Previous unknown bypass grafts or known left internal mammary graft
• Chest pain within 6 hours of IP administration
• More than 2 episodes of chest pain within 24 hours prior to IP administration
• Use of sublingual, transdermal, or intravenous nitroglycerine within 6 hours prior to IP administration
• Likely need for use of nitroglycerine for non-study indication
• Narcotic or sedative within 4 hours of enrollment
• Women who are suspected or known to be pregnant or breastfeeding

Where it is running

• Aultman Hospital — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.